Long-term safety and efficacy extension study data of Alprolix® for haemophilia B published in Thrombosis and Haemostasis
- Median prophylactic dosing interval of 13.7 days in 86% of adult/adolescent subjects in individualized Alprolix treatment group - Long-term safety and low annual bleed rate maintained in longest study of an extended half-life therapy for haemophilia BSwedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today announce that interim results from the B-YOND extension trial, which studies Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in previously treated subjects with severe